We are live on
!
Find out more
RC
Rangeley Capital Portfolio holdings
AUM
$103M
1-Year Est. Return
77.32%
This Fund
S&P 500
This Quarter
Est. Return
+20.64%
1 Year Est. Return
+77.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$83.8M
AUM Growth
-$9.56M
(-10%)
Cap. Flow
-$15.6M
Cap. Flow
% of AUM
-18.56%
Top 10 Holdings %
Top 10 Hldgs %
54.2%
Holding
117
New
40
Increased
13
Reduced
18
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prothena Corp
PRTA
|
+$5.37M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$2.54M |
| 3 |
ITOS
iTeos Therapeutics
ITOS
|
+$2.43M |
| 4 |
SKX
Skechers
SKX
|
+$2.07M |
| 5 |
Surgery Partners
SGRY
|
+$1.67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Burford Capital
BUR
|
+$3.92M |
| 2 |
Calumet Specialty Products
CLMT
|
+$2.55M |
| 3 |
Amplify Energy
AMPY
|
+$2.5M |
| 4 |
Liquidia Corp
LQDA
|
+$2.36M |
| 5 |
Par Pacific Holdings
PARR
|
+$2.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.94% |
| 2 | Energy | 12.53% |
| 3 | Real Estate | 8.38% |
| 4 | Consumer Discretionary | 7.77% |
| 5 | Materials | 7.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CRGX
51
DELISTED
CARGO Therapeutics
CRGX
| $172K | 0.21% |
41,851
-40,000
| -49% | -$171K |
|
|
KDK
52
Kodiak AI
KDK
$794M
| $135K | 0.16% |
+11,920
| New | +$134K |
|
|
GSRT
53
DELISTED
GSR III Acquisition Corp
GSRT
| $119K | 0.14% |
+11,000
| New | +$115K |
|
|
THTX
54
DELISTED
Theratechnologies
THTX
| $118K | 0.14% |
+50,000
| New | +$123K |
|
|
TMQ
55
Trilogy Metals
TMQ
$518M
| $117K | 0.14% |
87,000
-11,074
| -11% | -$15.6K |
|
|
MURA
56
DELISTED
Mural Oncology
MURA
| $115K | 0.14% |
+46,513
| New | +$110K |
|
|
SBXD
57
SilverBox Corp IV
SBXD
$276M
| $110K | 0.13% |
+10,000
| New | +$105K |
|
|
OKUR
58
OnKure Therapeutics
OKUR
$160M
| $71.5K | 0.09% |
+29,902
| New | +$78.4K |
|
59
Pliant Therapeutics
PLRX
$67.5M
| $69.9K | 0.08% |
60,220
+10,220
| +20% | +$14.4K |
|
60
AN2 Therapeutics
ANTX
$174M
| $68.9K | 0.08% |
65,000
+15,000
| +30% | +$17.9K |
|
61
4D Molecular Therapeutics
FDMT
$499M
| $48.2K | 0.06% |
+13,000
| New | +$45.7K |
|
|
AKYA
62
DELISTED
Akoya BioSciences
AKYA
| $42.9K | 0.05% |
+33,035
| New | +$39.7K |
|
63
Vivid Seats
SEAT
$87.8M
| $42.3K | 0.05% |
+1,250
| New | +$53.5K |
|
64
PepGen
PEPG
$125M
| $38.9K | 0.05% |
35,000
+20,000
| +133% | +$28.3K |
|
|
LVTX
65
DELISTED
LAVA Therapeutics
LVTX
| $35.7K | 0.04% |
+27,073
| New | +$34.5K |
|
66
MacroGenics
MGNX
$242M
| $32.7K | 0.04% |
+27,000
| New | +$39.2K |
|
67
Nuvation Bio
NUVB
$2.27B
| $25.4K | 0.03% |
+13,000
| New | +$27.1K |
|
|
LITS
68
Lite Strategy Inc
LITS
$33.1M
| $24.7K | 0.03% |
+10,000
| New | +$21.4K |
|
69
Cabaletta Bio
CABA
$439M
| $24.3K | 0.03% |
+16,000
| New | +$25K |
|
70
Zura Bio
ZURA
$510M
| $22.1K | 0.03% |
+21,000
| New | +$25.1K |
|
71
Seer Inc
SEER
$111M
| $21.4K | 0.03% |
+10,000
| New | +$20K |
|
|
SDEV
72
Stablecoin Development Corp
SDEV
$31.5M
| $19.3K | 0.02% |
+6,642
| New | +$19.1K |
|
|
SYBX
73
DELISTED
Synlogic
SYBX
| $17.3K | 0.02% |
+13,597
| New | +$15.7K |
|
74
Atlanta Braves Holdings Series B
BATRK
$3.28B
| – | – |
-5,981
| Closed | -$239K |
|
75
BridgeBio Pharma
BBIO
$16.5B
| – | – |
-13,000
| Closed | -$473K |
|
Similar funds
EFT
GWL
CC
ABLA
SPCM
OPAM
ES
IMT
Rangeley Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Rangeley Capital held 117 positions worth $83.8M, down 10% from $93.4M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Rangeley Capital withdrew a net $15.6M in Q2 2025, closing 44 positions and reducing 18 holdings. Its most notable exit was Liquidia Corp, an estimated $2.36M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 29% a quarter earlier, followed by Energy and Real Estate.
Against the trend, Rangeley Capital opened a new position in Prothena Corp worth $4.34M.
- Rangeley Capital's largest Q2 2025 buy was Prothena Corp: 715,367 shares worth $4.34M.
- Rangeley Capital added most to Sage Therapeutics in Q2 2025, an estimated $2.54M increase.
- Rangeley Capital's biggest Q2 2025 reduction was Burford Capital, cutting an estimated $3.92M.
- Rangeley Capital fully exited Liquidia Corp in Q2 2025, selling an estimated $2.36M.
- Rangeley Capital's ten largest holdings make up 54% of its $83.8M portfolio in Q2 2025.
- Rangeley Capital opened 40 new positions and closed 44 in Q2 2025.
- Rangeley Capital's portfolio value fell 10% quarter-over-quarter to $83.8M.
Based on Rangeley Capital's 13F filing for Q2 2025, filed 14 Aug 2025.